A New Immunotherapy Target Emerges in Kidney Cancer
A pivotal study published in *Cell Death & Differentiation* reveals a novel strategy to enhance antitumor immunity in clear cell renal cell carcinoma (ccRCC). Researchers have identified that inhibiting the enzyme DPP9 disrupts the BRISC deubiquitinase complex, which in turn suppresses PD-L1 expression on tumor cells. This mechanistic insight provides a direct link between metabolic regulation and immune checkpoint control within the tumor microenvironment. By targeting DPP9, the study demonstrates a significant boost in antitumor immune responses, offering a promising new avenue for combination therapies in immuno-oncology. This research underscores the importance of exploring non-canonical pathways regulating PD-L1 to overcome resistance to existing checkpoint inhibitors.
Study Significance: For oncologists and cancer biologists, this finding directly expands the toolkit for targeting the PD-1/PD-L1 axis, a cornerstone of modern immuno-oncology. It suggests that DPP9 inhibitors could be developed as a novel class of targeted therapy, potentially to re-sensitize tumors that have developed resistance to current checkpoint blockade. This moves precision oncology forward by identifying a specific, druggable target within the tumor’s immune evasion machinery, which could inform future clinical trial design for renal cell carcinoma and other solid tumors.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
